Orient Securities Company Limited sold 991,000 shares of KEYMED BIO-B (02162) on the SEHK open market at an average of HKD 70.8951 per share on October 27, 2026, involving about HKD 70.26 million; as an on-exchange active trade, it was a direct secondary-market dealing.
Prior to the disposal, Orient Securities Company Limited’s long position in KEYMED BIO-B was 15.19 million shares, representing 5.08%; following the disposal, the holding changed to 14.20 million shares, with the long position ratio falling to 4.75%.
Source: Hong Kong Exchanges and Clearing Limited.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments